{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:02:44Z","timestamp":1765609364882,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.clon.2008.04.006","type":"journal-article","created":{"date-parts":[[2008,6,6]],"date-time":"2008-06-06T04:41:18Z","timestamp":1212727278000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Human Papillomavirus Vaccines versus Cervical Cancer Screening"],"prefix":"10.1016","volume":"20","author":[{"given":"M.","family":"Stanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib2","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1001\/jama.286.24.3106","article-title":"Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia","volume":"286","author":"Schlecht","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2008.04.006_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/317638","article-title":"A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types","volume":"183","author":"Liaw","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clon.2008.04.006_bib4","article-title":"IARC monographs on the evaluation of carcinogen risks to humans","volume":"vol. 64","author":"International Agency for Research on Cancer","year":"1995"},{"issue":"Suppl 1","key":"10.1016\/j.clon.2008.04.006_bib5","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jcv.2004.12.006","article-title":"The papillomavirus life cycle","volume":"32","author":"Doorbar","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.clon.2008.04.006_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.vaccine.2006.05.115","article-title":"HPV in the etiology of human cancer","volume":"24","author":"Munoz","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib8","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.vaccine.2006.06.015","article-title":"Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.clon.2008.04.006_bib10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2008.04.006_bib12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199210293271804","article-title":"A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection","volume":"327","author":"Koutsky","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2008.04.006_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis","volume":"89","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib14","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"Munger","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.clon.2008.04.006_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clon.2008.04.006_bib16","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clon.2008.04.006_bib17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.65.2.219","article-title":"Immunization of rabbits to infectious papillomatosis","volume":"65","author":"Shope","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.clon.2008.04.006_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476","article-title":"Natural history of anogenital human papillomavirus infection and neoplasia","volume":"31","author":"Schiffman","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.clon.2008.04.006_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2008.04.006_bib21","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2008.04.006_bib22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2008.04.006_bib23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a\u00a0prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2008.04.006_bib24","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2008.04.006_bib25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2008.04.006_bib26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2008.04.006_bib27","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib28","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib29","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib30","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","article-title":"Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clon.2008.04.006_bib32","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1016\/j.vaccine.2007.06.059","article-title":"Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years","volume":"25","author":"Hammitt","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib33","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1016\/j.vaccine.2006.06.079","article-title":"Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects","volume":"24","author":"Veiga","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib34","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.clon.2008.04.006_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4161\/hv.3.4.4058","article-title":"Antibodies from women immunized with Gardasil ((R)) cross-neutralize HPV 45 pseudovirions","volume":"3","author":"Smith","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.clon.2008.04.006_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2008.04.006_bib39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.bjc.6602049","article-title":"Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort","volume":"91","author":"Peto","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib40","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.clon.2008.04.006_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.clon.2008.04.006_bib42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.39273.458322.BE","article-title":"Challenges of implementing human papillomavirus (HPV) vaccination policy","volume":"335","author":"Raffle","year":"2007","journal-title":"Br Med J"},{"key":"10.1016\/j.clon.2008.04.006_bib43","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clon.2008.04.006_bib44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.bjc.6600974","article-title":"Benefit of cervical screening at different ages: evidence from the UK audit of screening histories","volume":"89","author":"Sasieni","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1783\/147118908783332078","article-title":"Cervical screening: why young women should be encouraged to be screened","volume":"34","author":"Herbert","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib46","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.clon.2008.04.006_bib47","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2008.04.006_bib48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/14796694.3.3.319","article-title":"Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination","volume":"3","author":"Franco","year":"2007","journal-title":"Future Oncol"},{"key":"10.1016\/j.clon.2008.04.006_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bjc.6604146","article-title":"HPV and cervical cancer: screening or vaccination?","volume":"98","author":"Bosch","year":"2008","journal-title":"Br J Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib50","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.vaccine.2006.05.128","article-title":"HPV vaccine use in the developing world","volume":"24","author":"Kane","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.04.006_bib51","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.vaccine.2006.05.121","article-title":"Screening for cervical cancer in developing countries","volume":"24","author":"Denny","year":"2006","journal-title":"Vaccine"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655508002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655508002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:32:31Z","timestamp":1760542351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655508002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0936655508002070"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2008.04.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Papillomavirus Vaccines versus Cervical Cancer Screening","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2008.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}